Revised "iRR6" model in intermediate-1 risk myelofibrosis patients treated with ruxolitinib
Fuente:
Zenodo
Saved in:
| Main Authors: | PALANDRI, FRANCESCA, Branzanti, Filippo, ded, Alessandra |
|---|---|
| Format: | Recurso digital |
| Published: |
Zenodo
2024
|
| Online Access: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
Survival and quality‐of‐life implications of cytopenia trajectories in ruxolitinib‐treated myelofibrosis
by: Francesca Palandri, et al.
Published: (2026)
by: Francesca Palandri, et al.
Published: (2026)
Neutrophil to lymphocyte ratio in myelofibrosis patients treated with ruxolitinib may predict prognosis and rate of discontinuation
by: Alessandro Laganà, et al.
Published: (2024)
by: Alessandro Laganà, et al.
Published: (2024)
Oral administration of ruxolitinib in psoriasis vulgaris: A case report of plaque psoriasis accompanied by myelofibrosis secondary to polisitemia vera successfully treated with oral ruxolitinib
by: Tubanur Çetinarslan, et al.
Published: (2024)
by: Tubanur Çetinarslan, et al.
Published: (2024)
Exposure–response relationship of fedratinib in patients with intermediate‐2 or high‐risk myelofibrosis
by: Yizhe Chen, et al.
Published: (2025)
by: Yizhe Chen, et al.
Published: (2025)
Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real‐world setting: Interim results of the Italian observational study (ROMEI)
by: Massimo Breccia, et al.
Published: (2025)
by: Massimo Breccia, et al.
Published: (2025)
Refractory anogenital Hailey‐Hailey disease successfully treated with topical ruxolitinib
by: Sandra Ly, et al.
Published: (2025)
by: Sandra Ly, et al.
Published: (2025)
JAK2 is a critical therapeutic target in VEXAS syndrome treated with ruxolitinib
by: Andrea Ceccardi, et al.
Published: (2025)
by: Andrea Ceccardi, et al.
Published: (2025)
Programmed death‐ligand 1 expression in patients with primary or secondary myelofibrosis
by: Moayed Ibrahim, et al.
Published: (2024)
by: Moayed Ibrahim, et al.
Published: (2024)
Chapter Tracciare il senso di una vita. Wabinureba e Hisakata no nei codici della raccolta poetica di Komachi (Komachishū)
by: FRACCARO, FRANCESCA
Published: (2024)
by: FRACCARO, FRANCESCA
Published: (2024)
Predicatori nelle terre slavo-orientali (XI-XIII sec.)
by: ROMOLI, FRANCESCA
Published: (2022)
by: ROMOLI, FRANCESCA
Published: (2022)
The impact of heat stress in plant reproduction
by: RESENTINI, FRANCESCA
Published: (2023)
by: RESENTINI, FRANCESCA
Published: (2023)
Electrical resistivity tomography for the characterization of river embankments: 2D vs 3D inversion - Supplementary Material
by: PACE, FRANCESCA
Published: (2026)
by: PACE, FRANCESCA
Published: (2026)
Scarti, tracce e frammenti: controarchivio e memoria dell’umano
by: VALDINOCI, FRANCESCA
Published: (2022)
by: VALDINOCI, FRANCESCA
Published: (2022)
Chapter Ippolito Nievo e Luigi Meneghello: una lettura stratificata
by: DONAZZAN, FRANCESCA
Published: (2025)
by: DONAZZAN, FRANCESCA
Published: (2025)
Chapter La «Narrazione sul segno della croce» di Massimo il Greco: esegesi delle Scritture e prassi ortodossa nella Moscovia cinquecentesca
by: ROMOLI, FRANCESCA
Published: (2025)
by: ROMOLI, FRANCESCA
Published: (2025)
Chapter Μεσόγειος Θάλασσα (Mesogeios Thalassa) in the Reflection of Dizhonghai 地中海: Routes and Connections Between the Greek World and China
by: FARIELLO, FRANCESCA
Published: (2025)
by: FARIELLO, FRANCESCA
Published: (2025)
Chapter Solidarietà, doveri e cittadinanza europea
by: POLACCHINI, FRANCESCA
Published: (2022)
by: POLACCHINI, FRANCESCA
Published: (2022)
Chapter L’espressione della relazione concessiva fattuale in italiano e in russo
by: BIAGINI, FRANCESCA
Published: (2022)
by: BIAGINI, FRANCESCA
Published: (2022)
La monja no tiene quien la escuche. El caso de Dominga Gutiérrez y la prosa de la contra-emancipación*
by: FRANCESCA DENEGRI
Published: (2022)
by: FRANCESCA DENEGRI
Published: (2022)
“THE NORMAL EXCEPTION”: EDOARDO GRENDI, MICROANALYSIS, AND GENERALIZATIONS*
by: FRANCESCA TRIVELLATO
Published: (2026)
by: FRANCESCA TRIVELLATO
Published: (2026)
TRAS LAS HUELLAS DEL SISTEMA POLÍTICO VENEZOLANO: DOSCIENTOS AÑOS DE HISTORIA VERTIDOS EN UNA NUEVA REVOLUCIÓN
by: FRANCESCA RAMOS
Published: (2005)
by: FRANCESCA RAMOS
Published: (2005)
¡Haz lo correcto! Robert Alexy y la pretensión de corrección
by: FRANCESCA POGGI
Published: (2023)
by: FRANCESCA POGGI
Published: (2023)
Circulating micromegakaryocytes in an asplenic patient with post‐polycythemia myelofibrosis
by: Albert Borg, et al.
Published: (2024)
by: Albert Borg, et al.
Published: (2024)
Topical ruxolitinib for facial blaschkitis in an adolescent
by: Diana H. Zarowin, et al.
Published: (2024)
by: Diana H. Zarowin, et al.
Published: (2024)
Risk models in myelofibrosis—the past, present, and future
by: Ayalew Tefferi, et al.
Published: (2024)
by: Ayalew Tefferi, et al.
Published: (2024)
Outcomes of intermediate or high‐risk CMML patients treated with hypomethylating agents combined with venetoclax: A single center experience
by: Chao Li, et al.
Published: (2024)
by: Chao Li, et al.
Published: (2024)
Autoimmune myelofibrosis: A Mayo Clinic series of 22 patients
by: Naseema Gangat, et al.
Published: (2024)
by: Naseema Gangat, et al.
Published: (2024)
Improved outcomes in primary myelofibrosis patients with increased haemoglobin concentration
by: Ivan Krecak, et al.
Published: (2025)
by: Ivan Krecak, et al.
Published: (2025)
Chapter Genealogical Writing and Epigraphic Layout: Some Preliminary Remarks
by: MARCHIANDI, DANIELA FRANCESCA
Published: (2025)
by: MARCHIANDI, DANIELA FRANCESCA
Published: (2025)
Rischio di impresa e responsabilità civile
by: DEGL'INNOCENTI, FRANCESCA
Published: (2022)
by: DEGL'INNOCENTI, FRANCESCA
Published: (2022)
Una muchedumbre o nada
by: DI MEGLIO, FRANCESCA
Published: (2022)
by: DI MEGLIO, FRANCESCA
Published: (2022)
RESPUESTA A FOLFIRI-BEVACIZUMAB EN ADENOCARCINOMA ANAL AVANZADO. TUMOR HISTOLÓGICAMENTE FRECUENTE EN UN LUGAR POCO HABITUAL
by: FRANCESCA FILIPPI-ARRIAGA
Published: (2022)
by: FRANCESCA FILIPPI-ARRIAGA
Published: (2022)
Goodbye etoposide? Taking the leap to ruxolitinib in haemophagocytic lymphohistiocytosis
by: Samuel A. Merrill, et al.
Published: (2024)
by: Samuel A. Merrill, et al.
Published: (2024)
Ruxolitinib for myelofibrosis: The earlier, the better?
by: Prithviraj Bose, et al.
Published: (2024)
by: Prithviraj Bose, et al.
Published: (2024)
Correction to “Novel approaches in myelofibrosis”
Published: (2025)
Published: (2025)
Newly identified roles for PIEZO1 mechanosensor in controlling normal megakaryocyte development and in primary myelofibrosis
by: Vittorio Abbonante, et al.
Published: (2024)
by: Vittorio Abbonante, et al.
Published: (2024)
First direct detection of an RR Lyrae star conclusively associated with an intermediate-age cluster
by: Mateu, Cecilia, et al.
Published: (2025)
by: Mateu, Cecilia, et al.
Published: (2025)
Chapter The Binding Layout? On Graphic Strategies in Greek Magical Texts
by: Maltomini, Francesca, et al.
Published: (2025)
by: Maltomini, Francesca, et al.
Published: (2025)
Efficacy of ruxolitinib in the treatment of relapsed/refractory large granular lymphocytic leukaemia
by: Tony Marchand, et al.
Published: (2024)
by: Tony Marchand, et al.
Published: (2024)
From primary myelofibrosis to chronic myeloid leukemia, BCR::ABL1+ B‐Lymphoblastic leukemia, and back to primary myelofibrosis: An illustration of dynamic clonal evolution
by: Devin Wang, et al.
Published: (2024)
by: Devin Wang, et al.
Published: (2024)
Similar Items
-
Survival and quality‐of‐life implications of cytopenia trajectories in ruxolitinib‐treated myelofibrosis
by: Francesca Palandri, et al.
Published: (2026) -
Neutrophil to lymphocyte ratio in myelofibrosis patients treated with ruxolitinib may predict prognosis and rate of discontinuation
by: Alessandro Laganà, et al.
Published: (2024) -
Oral administration of ruxolitinib in psoriasis vulgaris: A case report of plaque psoriasis accompanied by myelofibrosis secondary to polisitemia vera successfully treated with oral ruxolitinib
by: Tubanur Çetinarslan, et al.
Published: (2024) -
Exposure–response relationship of fedratinib in patients with intermediate‐2 or high‐risk myelofibrosis
by: Yizhe Chen, et al.
Published: (2025) -
Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real‐world setting: Interim results of the Italian observational study (ROMEI)
by: Massimo Breccia, et al.
Published: (2025)